Maze Therapeutics, Inc. Common Stock (MAZE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Maze Therapeutics, Inc. Common Stock stock (MAZE) is currently trading at $31.73. Maze Therapeutics, Inc. Common Stock PS ratio (Price-to-Sales) is 3.14. Analyst consensus price target for MAZE is $59.73. WallStSmart rates MAZE as Sell.
- MAZE PE ratio analysis and historical PE chart
- MAZE PS ratio (Price-to-Sales) history and trend
- MAZE intrinsic value — DCF, Graham Number, EPV models
- MAZE stock price prediction 2025 2026 2027 2028 2029 2030
- MAZE fair value vs current price
- MAZE insider transactions and insider buying
- Is MAZE undervalued or overvalued?
- Maze Therapeutics, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- MAZE Piotroski F-Score and Altman Z-Score
- MAZE analyst price target and Smart Rating
Maze Therapeutics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Maze Therapeutics, Inc. Common Stock (MAZE) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and price/book. Significant fundamental concerns warrant caution or avoidance.
Maze Therapeutics, Inc. Common Stock (MAZE) Key Strengths (2)
100.12% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Maze Therapeutics, Inc. Common Stock (MAZE) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 6.1x book value
Revenue is fairly priced at 3.14x sales
Supporting Valuation Data
Maze Therapeutics, Inc. Common Stock (MAZE) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 2 register as strengths (avg 8.5/10) while 3 fall into concern territory (avg 2.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Return on Equity, Price/Book, Price/Sales. Some valuation metrics including Price/Sales (3.14), Price/Book (6.09) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -52.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -52.70% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MAZE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MAZE's Price-to-Sales ratio of 3.14x trades 45% below its historical average of 5.74x (11th percentile). The current valuation is 76% below its historical high of 13.17x set in Feb 2026, and 33% above its historical low of 2.36x in Apr 2025.
WallStSmart Analysis Synopsis
Data-driven financial summary for Maze Therapeutics, Inc. Common Stock (MAZE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Maze Therapeutics, Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -25M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Maze Therapeutics, Inc. Common Stock.
Bottom Line
Maze Therapeutics, Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:26:19 AM
About Maze Therapeutics, Inc. Common Stock(MAZE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. The company is headquartered in South San Francisco, California.